{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Nano-drug delivery", "Novel approaches", "Oligonucleotides", "Respiratory diseases", "miRNA", "siRNA"]], "SpaceFlightMission": [], "InvestigatorList": [], "OtherAbstract": [], "OtherID": [], "CitationSubset": ["IM"], "GeneralNote": [], "PMID": "31136735", "DateCompleted": {"Year": "2019", "Month": "07", "Day": "22"}, "DateRevised": {"Year": "2020", "Month": "04", "Day": "07"}, "Article": {"ArticleDate": [{"Year": "2019", "Month": "05", "Day": "25"}], "Language": ["eng"], "ELocationID": ["10.1016/j.cbi.2019.05.028", "S0009-2797(19)30575-7"], "Journal": {"ISSN": "1872-7786", "JournalIssue": {"Volume": "308", "PubDate": {"Year": "2019", "Month": "Aug", "Day": "01"}}, "Title": "Chemico-biological interactions", "ISOAbbreviation": "Chem Biol Interact"}, "ArticleTitle": "Oligonucleotide therapy: An emerging focus area for drug delivery in chronic inflammatory respiratory diseases.", "Pagination": {"StartPage": "206", "EndPage": "215", "MedlinePgn": "206-215"}, "Abstract": {"AbstractText": ["Oligonucleotide-based therapies are advanced novel interventions used in the management of various respiratory diseases such as asthma and Chronic Obstructive Pulmonary Disease (COPD). These agents primarily act by gene silencing or RNA interference. Better methodologies and techniques are the need of the hour that can deliver these agents to tissues and cells in a target specific manner by which their maximum potential can be reached in the management of chronic inflammatory diseases. Nanoparticles play an important role in the target-specific delivery of drugs. In addition, oligonucleotides also are extensively used for gene transfer in the form of polymeric, liposomal and inorganic carrier materials. Therefore, the current review focuses on various novel dosage forms like nanoparticles, liposomes that can be used efficiently for the delivery of various oligonucleotides such as siRNA and miRNA. We also discuss the future perspectives and targets for oligonucleotides in the management of respiratory diseases."], "CopyrightInformation": "Copyright \u00a9 2019 Elsevier B.V. All rights reserved."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Pharmaceutical Sciences, Lovely Professional University, Jalandhar-Delhi G.T. Road (NH-1), Phagwara, 144411, Punjab, India."}], "LastName": "Mehta", "ForeName": "Meenu", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Pharmaceutical Sciences, Lovely Professional University, Jalandhar-Delhi G.T. Road (NH-1), Phagwara, 144411, Punjab, India."}], "LastName": "Deeksha"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Pharmaceutical Sciences, Lovely Professional University, Jalandhar-Delhi G.T. Road (NH-1), Phagwara, 144411, Punjab, India."}], "LastName": "Tewari", "ForeName": "Devesh", "Initials": "D"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Phamacy, Suresh Gyan Vihar University, Jagatpura, Mahal Road, Jaipur, India."}], "LastName": "Gupta", "ForeName": "Gaurav", "Initials": "G"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Amity School of Pharmacy, Amity University, Noida, Uttar Pradesh, India."}], "LastName": "Awasthi", "ForeName": "Rajendra", "Initials": "R"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "National Medicinal Plants Board, Ministry of AYUSH, New Delhi, India."}], "LastName": "Singh", "ForeName": "Harjeet", "Initials": "H"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Sciences, Shri Baba Mastnath University, Rohtak, Haryana, 124001, India."}], "LastName": "Pandey", "ForeName": "Parijat", "Initials": "P"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Life Sciences, School of Pharmacy, International Medical University, Bukit Jalil, Kuala Lumpur, 57000, Malaysia."}], "LastName": "Chellappan", "ForeName": "Dinesh Kumar", "Initials": "DK"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Faculty of Life Science and Biotechnology, South Asian University, Akbar Bhawan, Chanakyapuri, New Delhi, 110021, India."}], "LastName": "Wadhwa", "ForeName": "Ridhima", "Initials": "R"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Indigenous Medicines Group, Institute of Health & Biomedical Innovation, Queensland University of Technology, Brisbane, Australia."}], "LastName": "Collet", "ForeName": "Trudi", "Initials": "T"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Centre for Inflammation, Centenary Institute, Sydney, NSW, 2050 Australia; School of Life Sciences, University of Technology Sydney, Sydney, NSW, Australia; Priority Research Centre for Healthy Lungs, Hunter Medical Research Institute (HMRI) & School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, NSW, 2308, Australia."}], "LastName": "Hansbro", "ForeName": "Philip M", "Initials": "PM"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Nanobiomedicine Lab, Department of Pharmacology, Saveetha Dental College, Saveetha Institute of Medical and Technical Sciences, Chennai, 600077, Tamil Nadu, India."}], "LastName": "Kumar", "ForeName": "S Rajesh", "Initials": "SR"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Nanobiomedicine Lab, Department of Pharmacology, Saveetha Dental College, Saveetha Institute of Medical and Technical Sciences, Chennai, 600077, Tamil Nadu, India."}], "LastName": "Thangavelu", "ForeName": "Lakshmi", "Initials": "L"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Pharmaceutical Sciences, Shoolini University, Solan, Himachal Pradesh, India."}], "LastName": "Negi", "ForeName": "Poonam", "Initials": "P"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Centre for Inflammation, Centenary Institute, Sydney, NSW, 2050 Australia; Priority Research Centre for Healthy Lungs, Hunter Medical Research Institute (HMRI) & School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, NSW, 2308, Australia; Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Ultimo, NSW, 2007, Australia. Electronic address: Kamal.Dua@uts.edu.au."}], "LastName": "Dua", "ForeName": "Kamal", "Initials": "K"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Pharmaceutical Sciences, Lovely Professional University, Jalandhar-Delhi G.T. Road (NH-1), Phagwara, 144411, Punjab, India. Electronic address: saurabh.21958@lpu.co.in."}], "LastName": "Satija", "ForeName": "Saurabh", "Initials": "S"}], "PublicationTypeList": ["Journal Article", "Review"]}, "MedlineJournalInfo": {"Country": "Ireland", "MedlineTA": "Chem Biol Interact", "NlmUniqueID": "0227276", "ISSNLinking": "0009-2797"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Dendrimers"}, {"RegistryNumber": "0", "NameOfSubstance": "Drug Carriers"}, {"RegistryNumber": "0", "NameOfSubstance": "Liposomes"}, {"RegistryNumber": "0", "NameOfSubstance": "MicroRNAs"}, {"RegistryNumber": "0", "NameOfSubstance": "Oligonucleotides, Antisense"}, {"RegistryNumber": "0", "NameOfSubstance": "RNA, Small Interfering"}], "MeshHeadingList": [{"QualifierName": ["chemistry"], "DescriptorName": "Dendrimers"}, {"QualifierName": ["chemistry"], "DescriptorName": "Drug Carriers"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["chemistry"], "DescriptorName": "Liposomes"}, {"QualifierName": ["chemistry", "therapeutic use"], "DescriptorName": "MicroRNAs"}, {"QualifierName": ["chemistry"], "DescriptorName": "Nanoparticles"}, {"QualifierName": ["chemistry", "therapeutic use"], "DescriptorName": "Oligonucleotides, Antisense"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Pulmonary Disease, Chronic Obstructive"}, {"QualifierName": [], "DescriptorName": "RNA Interference"}, {"QualifierName": ["chemistry", "therapeutic use"], "DescriptorName": "RNA, Small Interfering"}], "CoiStatement": "The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper."}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Mehta M., Deeksha, Sharma N., Vyas M., Khurana N., Maurya P.K., Singh H., Andreoli de Jesus T.P., Dureja H., Chellappan D.K., Gupta G., Wadhwa R., Collet T., Hansbro P.M., Dua K., Satija S. Interactions with the macrophages: an emerging targeted approach using novel drug delivery systems in respiratory diseases. Chem. Biol. Interact. 2019;304:10\u201319. doi: 10.1016/j.cbi.2019.02.021.", "ArticleIdList": ["10.1016/j.cbi.2019.02.021", "30849336"]}, {"Citation": "Dua K., Malyla V., Singhvi G., Wadhwa R., Krishna R.V., Shukla S.D., Shastri M.D., Chellappan D.K., Maurya P.K., Satija S., Mehta M., Gulati M., Hansbro N., Collet T., Awasthi R., Gupta G., Hsu A., Hansbro P.M. Increasing complexity and interactions of oxidative stress in chronic respiratory diseases: an emerging need for novel drug delivery systems. Chem. Biol. Interact. 2019;299:168\u2013178. doi: 10.1016/j.cbi.2018.12.009.", "ArticleIdList": ["10.1016/j.cbi.2018.12.009", "30553721"]}, {"Citation": "Dua K., Rapalli V.K., Shukla S.D., Singhvi G., Shastri M.D., Chellappan D.K., Satija S., Mehta M., Gulati M., Pinto T.D.J.A., Gupta G., Hansbro P.M. Multi-drug resistant Mycobacterium tuberculosis & oxidative stress complexity: emerging need for novel drug delivery approaches. Biomed. Pharmacother. 2018;107:1218\u20131229. doi: 10.1016/j.biopha.2018.08.101.", "ArticleIdList": ["10.1016/j.biopha.2018.08.101", "30257336"]}, {"Citation": "Qiu Y., Lam J.K.W., Leung S.W.S., Liang W. Delivery of RNAi therapeutics to the airways-from bench to bedside. Molecules. 2016;21 doi: 10.3390/molecules21091249.", "ArticleIdList": ["10.3390/molecules21091249", "PMC6272875", "27657028"]}, {"Citation": "Seguin R.M., Ferrari N. Emerging oligonucleotide therapies for asthma and chronic obstructive pulmonary disease. Expert Opin. Investig. Drugs. 2009;18:1505\u20131517. doi: 10.1517/13543780903179294.", "ArticleIdList": ["10.1517/13543780903179294", "19715448"]}, {"Citation": "Ferrari N., Seguin R., Renzi P. Oligonucleotides: a multi-targeted approach for the treatment of respiratory diseases. Future Med. Chem. 2011;3:1647\u20131662. doi: 10.4155/fmc.11.108.", "ArticleIdList": ["10.4155/fmc.11.108", "21942254"]}, {"Citation": "Rinaldi C., Wood M.J.A. Antisense oligonucleotides: the next frontier for treatment of neurological disorders. Nat. Rev. Neurol. 2018;14:9\u201321. doi: 10.1038/nrneurol.2017.148.", "ArticleIdList": ["10.1038/nrneurol.2017.148", "29192260"]}, {"Citation": "Kole R., Krainer A.R., Altman S. RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat. Rev. Drug Discov. 2012;11:125\u2013140. doi: 10.1038/nrd3625.", "ArticleIdList": ["10.1038/nrd3625", "PMC4743652", "22262036"]}, {"Citation": "Lam J.K.W., Chow M.Y.T., Zhang Y., Leung S.W.S. siRNA versus miRNA as therapeutics for gene silencing. Mol. Ther. Nucleic Acids. 2015;4 doi: 10.1038/mtna.2015.23. e252.", "ArticleIdList": ["10.1038/mtna.2015.23", "PMC4877448", "26372022"]}, {"Citation": "Dua K., Hansbro N.G., Foster P.S., Hansbro P.M. MicroRNAs as therapeutics for future drug delivery systems in treatment of lung diseases. Drug Deliv. Transl. Res. 2017;7:168\u2013178. doi: 10.1007/s13346-016-0343-6.", "ArticleIdList": ["10.1007/s13346-016-0343-6", "27848224"]}, {"Citation": "Dua K., Shukla S.D., de Jesus Andreoli Pinto T., Hansbro P.M. Nanotechnology: advancing the translational respiratory research. Interv. Med. Appl. Sci. 2017;9:39\u201341. doi: 10.1556/1646.9.2017.1.02.", "ArticleIdList": ["10.1556/1646.9.2017.1.02", "PMC5598120", "28932494"]}, {"Citation": "Wahid F., Shehzad A., Khan T., Kim Y.Y. MicroRNAs: synthesis, mechanism, function, and recent clinical trials. Biochim. Biophys. Acta. 2010;1803:1231\u20131243. doi: 10.1016/j.bbamcr.2010.06.013.", "ArticleIdList": ["10.1016/j.bbamcr.2010.06.013", "20619301"]}, {"Citation": "Rothlisberger P., Hollenstein M. Aptamer chemistry. Adv. Drug Deliv. Rev. 2018;134:3\u201321. doi: 10.1016/j.addr.2018.04.007.", "ArticleIdList": ["10.1016/j.addr.2018.04.007", "29626546"]}, {"Citation": "Song K.-M., Lee S., Ban C. Aptamers and their biological applications. Sensors. 2012;12:612\u2013631. doi: 10.3390/s120100612.", "ArticleIdList": ["10.3390/s120100612", "PMC3279232", "22368488"]}, {"Citation": "Shirota H., Tross D., Klinman D.M. CpG oligonucleotides as cancer vaccine adjuvants. Vaccines. 2015;3:390\u2013407. doi: 10.3390/vaccines3020390.", "ArticleIdList": ["10.3390/vaccines3020390", "PMC4494345", "26343193"]}, {"Citation": "Sah D.W.Y., Aronin N. Oligonucleotide therapeutic approaches for Huntington disease. J. Clin. Investig. 2011;121:500\u2013507. doi: 10.1172/JCI45130.", "ArticleIdList": ["10.1172/JCI45130", "PMC3026739", "21285523"]}, {"Citation": "Scoles D.R., Pulst S.M. Oligonucleotide therapeutics in neurodegenerative diseases. RNA Biol. 2018;15:707\u2013714. doi: 10.1080/15476286.2018.1454812.", "ArticleIdList": ["10.1080/15476286.2018.1454812", "PMC6152438", "29560813"]}, {"Citation": "Tanaka M., Nyce J.W. Respirable antisense oligonucleotides: a new drug class for respiratory disease. Respir. Res. 2001;2:5\u20139. doi: 10.1186/rr32.", "ArticleIdList": ["10.1186/rr32", "PMC59563", "11686859"]}, {"Citation": "Moreno P.M.D., P\u00eago A.P. Therapeutic antisense oligonucleotides against cancer: hurdling to the clinic. Front. Chem. 2014;2:87. doi: 10.3389/fchem.2014.00087.", "ArticleIdList": ["10.3389/fchem.2014.00087", "PMC4196572", "25353019"]}, {"Citation": "Hnik P., Boyer D.S., Grillone L.R., Clement J.G., Henry S.P., Green E.A. Antisense oligonucleotide therapy in diabetic retinopathy. J. Diabetes Sci. Technol. 2009;3:924\u2013930. doi: 10.1177/193229680900300440.", "ArticleIdList": ["10.1177/193229680900300440", "PMC2769949", "20144342"]}, {"Citation": "Zamecnik P.C., Stephenson M.L. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc. Natl. Acad. Sci. U.S.A. 1978;75:280\u2013284. https://www.ncbi.nlm.nih.gov/pubmed/75545", "ArticleIdList": ["PMC411230", "75545"]}, {"Citation": "Paolo R., Zemzoumi K., D\u2019anjou H. 2009. Oligonucleotide Compositions and Methods for Treating Disease Including Inflammatory Conditions."}, {"Citation": "Barik S. 1998. Antisense Oligonucleotides against Nonstructural Proteins NS1 and NS2 of Respiratory Syncytial Virus and Uses Thereof."}, {"Citation": "Klinman D.M., Yamada H. 2011. Method of Treating Inflammatory Lung Disease with Suppressors of CpG Oligonucleotides."}, {"Citation": "Krieg A., Weiner G. 2002. Methods and Products for Stimulating the Immune System Using Immunotherapeutic Oligonucleotides and Cytokines."}, {"Citation": "Zhang S., Zhi D., Huang L. Lipid-based vectors for siRNA delivery. J. Drug Target. 2012;20:724\u2013735. doi: 10.3109/1061186X.2012.719232.", "ArticleIdList": ["10.3109/1061186X.2012.719232", "PMC5006685", "22994300"]}, {"Citation": "Bheemidi V.S., Tiruckovela M., Varanasi P. An imperative note on novel drug delivery systems. J. Nanomed. Nanotech. 2011;2 EISSN 2157-7439 \u0411\u0418\u0411\u041b\u0418\u041e\u041c\u0415\u0422\u0420\u0418\u0427\u0415\u0421\u041a\u0418\u0415 \u041f\u041e\u041a\u0410\u0417\u0410\u0422\u0415\u041b\u0418 \u0412\u0445\u043e\u0434\u0438\u0442 \u0432 \u0420\u0418\u041d\u0426\u00ae \u0414\u0430 \u0426\u0438\u0442\u0438\u0440\u043e\u0432\u0430\u043d\u0438\u0439 \u0432 \u0420\u0418\u041d\u0426\u00ae 0 \u0412\u0445\u043e\u0434\u0438\u0442 \u0432 \u042f\u0434\u0440\u043e \u0420\u0418\u041d\u0426\u00ae \u041d\u0435\u0442 \u0426\u0438\u0442\u0438\u0440\u043e\u0432\u0430\u043d\u0438\u0439 \u0418\u0437 \u042f\u0434\u0440\u0430 \u0420\u0418\u041d\u0426\u00ae 0 \u0412\u0445\u043e\u0434\u0438\u0442 \u0432 Scopus\u00ae \u0426\u0438\u0442\u0438\u0440\u043e\u0432\u0430\u043d\u0438\u0439 \u0432 Scopus\u00ae \u0412\u0445\u043e\u0434\u0438\u0442 \u0432 Web Sci. \u0426\u0438."}, {"Citation": "McCaskill J., Singhania R., Burgess M., Allavena R., Wu S., Blumenthal A., McMillan N.A. Efficient biodistribution and gene silencing in the lung epithelium via intravenous liposomal delivery of siRNA. Mol. Ther. Nucleic Acids. 2013;2 doi: 10.1038/mtna.2013.22. e96\u2013e96.", "ArticleIdList": ["10.1038/mtna.2013.22", "PMC3696903", "23736774"]}, {"Citation": "Hattori Y., Nakamura M., Takeuchi N., Tamaki K., Shimizu S., Yoshiike Y., Taguchi M., Ohno H., Ozaki K.-I., Onishi H. Effect of cationic lipid in cationic liposomes on siRNA delivery into the lung by intravenous injection of cationic lipoplex. J. Drug Target. 2019;27:217\u2013227. doi: 10.1080/1061186X.2018.1502775.", "ArticleIdList": ["10.1080/1061186X.2018.1502775", "30024300"]}, {"Citation": "Ozpolat B., Sood A.K., Lopez-Berestein G. Nanomedicine based approaches for the delivery of siRNA in cancer. J. Intern. Med. 2010;267:44\u201353. doi: 10.1111/j.1365-2796.2009.02191.x.", "ArticleIdList": ["10.1111/j.1365-2796.2009.02191.x", "20059643"]}, {"Citation": "Gursel I., Gursel M., Ishii K.J., Klinman D.M. Sterically stabilized cationic liposomes improve the uptake and immunostimulatory activity of CpG oligonucleotides. J. Immunol. 2001;167:3324\u20133328.", "ArticleIdList": ["11544321"]}, {"Citation": "Li F., Mei H., Gao Y., Xie X., Nie H., Li T., Zhang H., Jia L. Co-delivery of oxygen and erlotinib by aptamer-modified liposomal complexes to reverse hypoxia-induced drug resistance in lung cancer. Biomaterials. 2017;145:56\u201371. doi: 10.1016/j.biomaterials.2017.08.030.", "ArticleIdList": ["10.1016/j.biomaterials.2017.08.030", "28843733"]}, {"Citation": "Garbuzenko O.B., Saad M., Betigeri S., Zhang M., Vetcher A.A., Soldatenkov V.A., Reimer D.C., Pozharov V.P., Minko T. Intratracheal versus intravenous liposomal delivery of siRNA, antisense oligonucleotides and anticancer drug. Pharm. Res. (N. Y.) 2009;26:382\u2013394. doi: 10.1007/s11095-008-9755-4.", "ArticleIdList": ["10.1007/s11095-008-9755-4", "18958402"]}, {"Citation": "Mizuta T., Fujiwara M., Hatta T., Abe T., Miyano-Kurosaki N., Shigeta S., Yokota T., Takaku H. Antisense oligonucleotides directed against the viral RNA polymerase gene enhance survival of mice infected with influenza A. Nat. Biotechnol. 1999;17:583\u2013587. doi: 10.1038/9893.", "ArticleIdList": ["10.1038/9893", "10385324"]}, {"Citation": "Otsuka M., Shiratori M., Chiba H., Kuronuma K., Sato Y., Niitsu Y., Takahashi H. Treatment of pulmonary fibrosis with siRNA against a collagen-specific chaperone HSP47 in vitamin A-coupled liposomes. Exp. Lung Res. 2017;43:271\u2013282. doi: 10.1080/01902148.2017.1354946.", "ArticleIdList": ["10.1080/01902148.2017.1354946", "29035148"]}, {"Citation": "Kazi K.M., Mandal A.S., Biswas N., Guha A., Chatterjee S., Behera M., Kuotsu K. Niosome: a future of targeted drug delivery systems. J. Adv. Pharm. Technol. Research (JAPTR) 2010;1:374\u2013380. doi: 10.4103/0110-5558.76435.", "ArticleIdList": ["10.4103/0110-5558.76435", "PMC3255404", "22247876"]}, {"Citation": "Ge X., Wei M., He S., Yuan W.-E. Advances of non-ionic surfactant vesicles (niosomes) and their application in drug delivery. Pharmaceutics. 2019;11 doi: 10.3390/pharmaceutics11020055.", "ArticleIdList": ["10.3390/pharmaceutics11020055", "PMC6410054", "30700021"]}, {"Citation": "Omlor A.J., Nguyen J., Bals R., Dinh Q.T. Nanotechnology in respiratory medicine. Respir. Res. 2015;16:64. doi: 10.1186/s12931-015-0223-5.", "ArticleIdList": ["10.1186/s12931-015-0223-5", "PMC4456054", "26021823"]}, {"Citation": "Grzelczak M., Vermant J., Furst E.M., Liz-Marzan L.M. Directed self-assembly of nanoparticles. ACS Nano. 2010;4:3591\u20133605. doi: 10.1021/nn100869j.", "ArticleIdList": ["10.1021/nn100869j", "20568710"]}, {"Citation": "Tiwari G., Tiwari R., Sriwastawa B., Bhati L., Pandey S., Pandey P., Bannerjee S.K. Drug delivery systems: an updated review. Int. J. Pharm. Investig. 2012;2:2.", "ArticleIdList": ["PMC3465154", "23071954"]}, {"Citation": "Crucho C.I.C., Barros M.T. Polymeric nanoparticles: a study on the preparation variables and characterization methods. Mater. Sci. Eng. C. 2017;80:771\u2013784.", "ArticleIdList": ["28866227"]}, {"Citation": "Kumar M., Kong X., Behera A.K., Hellermann G.R., Lockey R.F., Mohapatra S.S. Chitosan IFN-\u03b3-pDNA nanoparticle (CIN) therapy for allergic asthma. Genet. Vaccines Ther. 2003 doi: 10.1186/1479-0556-1-3.", "ArticleIdList": ["10.1186/1479-0556-1-3", "PMC280670", "14613519"]}, {"Citation": "Kline J.N., Waldschmidt T.J., Businga T.R., Lemish J.E., V Weinstock J., Thorne P.S., Krieg A.M. Cutting edge: modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma. J. Immunol. 1998;160:2555\u20132559.", "ArticleIdList": ["9510150"]}, {"Citation": "von Beust B.R., Johansen P., Smith K.A., Bot A., Storni T., Kundig T.M. Improving the therapeutic index of CpG oligodeoxynucleotides by intralymphatic administration. Eur. J. Immunol. 2005;35:1869\u20131876. doi: 10.1002/eji.200526124.", "ArticleIdList": ["10.1002/eji.200526124", "15909311"]}, {"Citation": "Joshi V.B., Adamcakova-Dodd A., Jing X., Wongrakpanich A., Gibson-Corley K.N., Thorne P.S., Salem A.K. Development of a poly (lactic-co-glycolic acid) particle vaccine to protect against house dust mite induced allergy. AAPS J. 2014;16:975\u2013985. doi: 10.1208/s12248-014-9624-5.", "ArticleIdList": ["10.1208/s12248-014-9624-5", "PMC4147059", "24981892"]}, {"Citation": "Xie Y., Kim N.H., Nadithe V., Schalk D., Thakur A., Kilic A., Lum L.G., Bassett D.J.P., Merkel O.M. Targeted delivery of siRNA to activated T cells via transferrin-polyethylenimine (Tf-PEI) as a potential therapy of asthma. J. Control. Release. 2016;229:120\u2013129. doi: 10.1016/j.jconrel.2016.03.029.", "ArticleIdList": ["10.1016/j.jconrel.2016.03.029", "PMC4886848", "27001893"]}, {"Citation": "Wang X., Xu W., Mohapatra S., Kong X., Li X., Lockey R.F., Mohapatra S.S. Prevention of airway inflammation with topical cream containing imiquimod and small interfering RNA for natriuretic peptide receptor. Genet. Vaccines Ther. 2008;6:7. doi: 10.1186/1479-0556-6-7.", "ArticleIdList": ["10.1186/1479-0556-6-7", "PMC2291050", "18279512"]}, {"Citation": "Sermet-Gaudelus I., Clancy J.P., Nichols D.P., Nick J.A., De Boeck K., Solomon G.M., Mall M.A., Bolognese J., Bouisset F., den Hollander W., Paquette-Lamontagne N., Tomkinson N., Henig N., Elborn J.S., Rowe S.M. Antisense oligonucleotide eluforsen improves CFTR function in F508del cystic fibrosis. J. Cyst. Fibros. 2018 doi: 10.1016/j.jcf.2018.10.015.", "ArticleIdList": ["10.1016/j.jcf.2018.10.015", "PMC7227803", "30467074"]}, {"Citation": "Osman G., Rodriguez J., Chan S.Y., Chisholm J., Duncan G., Kim N., Tatler A.L., Shakesheff K.M., Hanes J., Suk J.S., Dixon J.E. PEGylated enhanced cell penetrating peptide nanoparticles for lung gene therapy. J. Control. Release. 2018;285:35\u201345. doi: 10.1016/j.jconrel.2018.07.001.", "ArticleIdList": ["10.1016/j.jconrel.2018.07.001", "PMC6573017", "30004000"]}, {"Citation": "Xu C.-X., Jere D., Jin H., Chang S.-H., Chung Y.-S., Shin J.-Y., Kim J.-E., Park S.-J., Lee Y.-H., Chae C.-H., Lee K.H., Beck G.R.J., Cho C.-S., Cho M.-H. Poly(ester amine)-mediated, aerosol-delivered Akt1 small interfering RNA suppresses lung tumorigenesis. Am. J. Respir. Crit. Care Med. 2008;178:60\u201373. doi: 10.1164/rccm.200707-1022OC.", "ArticleIdList": ["10.1164/rccm.200707-1022OC", "PMC2441927", "18310482"]}, {"Citation": "Sung D.K., Kong W.H., Park K., Kim J.H., Kim M.Y., Kim H., Hahn S.K. Noncovalenly PEGylated CTGF siRNA/PDMAEMA complex for pulmonary treatment of bleomycin-induced lung fibrosis. Biomaterials. 2013;34:1261\u20131269. doi: 10.1016/j.biomaterials.2012.09.061.", "ArticleIdList": ["10.1016/j.biomaterials.2012.09.061", "23102621"]}, {"Citation": "Nafee N., Schneider M., Friebel K., Dong M., Schaefer U.F., Murdter T.E., Lehr C.-M. Treatment of lung cancer via telomerase inhibition: self-assembled nanoplexes versus polymeric nanoparticles as vectors for 2\u2019-O-Methyl-RNA. Eur. J. Pharm. Biopharm. 2012;80:478\u2013489. doi: 10.1016/j.ejpb.2011.11.019.", "ArticleIdList": ["10.1016/j.ejpb.2011.11.019", "22198416"]}, {"Citation": "Nascimento A.V., Singh A., Bousbaa H., Ferreira D., Sarmento B., Amiji M.M. Overcoming cisplatin resistance in non-small cell lung cancer with Mad2 silencing siRNA delivered systemically using EGFR-targeted chitosan nanoparticles. Acta Biomater. 2017;47:71\u201380. doi: 10.1016/j.actbio.2016.09.045.", "ArticleIdList": ["10.1016/j.actbio.2016.09.045", "PMC5110398", "27697601"]}, {"Citation": "Paranjpe M., Muller-Goymann C.C. Nanoparticle-mediated pulmonary drug delivery: a review. Int. J. Mol. Sci. 2014;15:5852\u20135873. doi: 10.3390/ijms15045852.", "ArticleIdList": ["10.3390/ijms15045852", "PMC4013600", "24717409"]}, {"Citation": "Bae K.H., Lee J.Y., Lee S.H., Park T.G., Nam Y.S. Optically traceable solid lipid nanoparticles loaded with siRNA and paclitaxel for synergistic chemotherapy with in situ imaging. Adv. Healthc. Mater. 2013;2:576\u2013584. doi: 10.1002/adhm.201200338.", "ArticleIdList": ["10.1002/adhm.201200338", "23184673"]}, {"Citation": "Taratula O., Kuzmov A., Shah M., Garbuzenko O.B., Minko T. Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA. J. Control. Release. 2013;171:349\u2013357. doi: 10.1016/j.jconrel.2013.04.018.", "ArticleIdList": ["10.1016/j.jconrel.2013.04.018", "PMC3766401", "23648833"]}, {"Citation": "Taratula O., Garbuzenko O.B., Chen A.M., Minko T. Innovative strategy for treatment of lung cancer: targeted nanotechnology-based inhalation co-delivery of anticancer drugs and siRNA. J. Drug Target. 2011;19:900\u2013914. doi: 10.3109/1061186X.2011.622404.", "ArticleIdList": ["10.3109/1061186X.2011.622404", "21981718"]}, {"Citation": "Conde J., Tian F., Hernandez Y., Bao C., Cui D., Janssen K.-P., Ibarra M.R., V Baptista P., Stoeger T., de la Fuente J.M. In vivo tumor targeting via nanoparticle-mediated therapeutic siRNA coupled to inflammatory response in lung cancer mouse models. Biomaterials. 2013;34:7744\u20137753. doi: 10.1016/j.biomaterials.2013.06.041.", "ArticleIdList": ["10.1016/j.biomaterials.2013.06.041", "23850099"]}, {"Citation": "de Fougerolles A., Novobrantseva T. siRNA and the lung: research tool or therapeutic drug? Curr. Opin. Pharmacol. 2008;8:280\u2013285. doi: 10.1016/j.coph.2008.04.005.", "ArticleIdList": ["10.1016/j.coph.2008.04.005", "PMC7106383", "18485820"]}, {"Citation": "Liao W., Dong J., Peh H.Y., Tan L.H., Lim K.S., Li L., Wong W.-S.F. Oligonucleotide therapy for obstructive and restrictive respiratory diseases. Molecules. 2017;22 doi: 10.3390/molecules22010139.", "ArticleIdList": ["10.3390/molecules22010139", "PMC6155767", "28106744"]}, {"Citation": "Braasch D.A., Paroo Z., Constantinescu A., Ren G., Oz O.K., Mason R.P., Corey D.R. Biodistribution of phosphodiester and phosphorothioate siRNA. Bioorg. Med. Chem. Lett. 2004;14:1139\u20131143. doi: 10.1016/j.bmcl.2003.12.074.", "ArticleIdList": ["10.1016/j.bmcl.2003.12.074", "14980652"]}, {"Citation": "Dykxhoorn D.M., Lieberman J. Running interference: prospects and obstacles to using small interfering RNAs as small molecule drugs. Annu. Rev. Biomed. Eng. 2006;8:377\u2013402. doi: 10.1146/annurev.bioeng.8.061505.095848.", "ArticleIdList": ["10.1146/annurev.bioeng.8.061505.095848", "16834561"]}, {"Citation": "Merkel O.M., Kissel T. Nonviral pulmonary delivery of siRNA. Acc. Chem. Res. 2012;45:961\u2013970. doi: 10.1021/ar200110p.", "ArticleIdList": ["10.1021/ar200110p", "21905687"]}, {"Citation": "Dua K., Bebawy M., Awasthi R., Tekade R.K., Tekade M., Gupta G., De Jesus Andreoli Pinto T., Hansbro P.M. Application of chitosan and its derivatives in nanocarrier based pulmonary drug delivery systems. Pharm. Nanotechnol. 2017;5:243\u2013249. doi: 10.2174/2211738505666170808095258.", "ArticleIdList": ["10.2174/2211738505666170808095258", "28786352"]}, {"Citation": "Leong K.W., Mao H.Q., Truong-Le V.L., Roy K., Walsh S.M., August J.T. DNA-polycation nanospheres as non-viral gene delivery vehicles. J. Control. Release. 1998;53:183\u2013193.", "ArticleIdList": ["9741926"]}, {"Citation": "Bacon A., Makin J., Sizer P.J., Jabbal-Gill I., Hinchcliffe M., Illum L., Chatfield S., Roberts M. Carbohydrate biopolymers enhance antibody responses to mucosally delivered vaccine antigens. Infect. Immun. 2000;68:5764\u20135770.", "ArticleIdList": ["PMC101535", "10992483"]}, {"Citation": "Koping-Hoggard M., Tubulekas I., Guan H., Edwards K., Nilsson M., Varum K.M., Artursson P. Chitosan as a nonviral gene delivery system. Structure-property relationships and characteristics compared with polyethylenimine in vitro and after lung administration in vivo. Gene Ther. 2001;8:1108\u20131121. doi: 10.1038/sj.gt.3301492.", "ArticleIdList": ["10.1038/sj.gt.3301492", "11526458"]}, {"Citation": "Howard K.A., Kjems J. Polycation-based nanoparticle delivery for improved RNA interference therapeutics. Expert Opin. Biol. Ther. 2007;7:1811\u20131822. doi: 10.1517/14712598.7.12.1811.", "ArticleIdList": ["10.1517/14712598.7.12.1811", "18034647"]}, {"Citation": "Howard K.A., Rahbek U.L., Liu X., Damgaard C.K., Glud S.Z., Andersen M.O., Hovgaard M.B., Schmitz A., Nyengaard J.R., Besenbacher F., Kjems J. RNA interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system. Mol. Ther. 2006;14:476\u2013484. doi: 10.1016/j.ymthe.2006.04.010.", "ArticleIdList": ["10.1016/j.ymthe.2006.04.010", "16829204"]}, {"Citation": "Liu X., Howard K.A., Dong M., Andersen M.O., Rahbek U.L., Johnsen M.G., Hansen O.C., Besenbacher F., Kjems J. The influence of polymeric properties on chitosan/siRNA nanoparticle formulation and gene silencing. Biomaterials. 2007;28:1280\u20131288. doi: 10.1016/j.biomaterials.2006.11.004.", "ArticleIdList": ["10.1016/j.biomaterials.2006.11.004", "17126901"]}, {"Citation": "Borchard G., Lue\u03b2en H.L., de Boer A.G., Verhoef J.C., Lehr C.-M., Junginger H.E. The potential of mucoadhesive polymers in enhancing intestinal peptide drug absorption. III: effects of chitosan-glutamate and carbomer on epithelial tight junctions in vitro. J. Control. Release. 1996;39:131\u2013138. doi: 10.1016/0168-3659(95)00146-8.", "ArticleIdList": ["10.1016/0168-3659(95)00146-8"]}, {"Citation": "Kong X., Zhang W., Lockey R.F., Auais A., Piedimonte G., Mohapatra S.S. Respiratory syncytial virus infection in Fischer 344 rats is attenuated by short interfering RNA against the RSV-NS1 gene. Genet. Vaccines Ther. 2007;5:4. doi: 10.1186/1479-0556-5-4.", "ArticleIdList": ["10.1186/1479-0556-5-4", "PMC1805440", "17270047"]}, {"Citation": "Zhang W., Yang H., Kong X., Mohapatra S., San Juan-Vergara H., Hellermann G., Behera S., Singam R., Lockey R.F., Mohapatra S.S. Inhibition of respiratory syncytial virus infection with intranasal siRNA nanoparticles targeting the viral NS1 gene. Nat. Med. 2005;11:56\u201362. doi: 10.1038/nm1174.", "ArticleIdList": ["10.1038/nm1174", "15619625"]}, {"Citation": "Bivas-Benita M., van Meijgaarden K.E., Franken K.L.M.C., Junginger H.E., Borchard G., Ottenhoff T.H.M., Geluk A. Pulmonary delivery of chitosan-DNA nanoparticles enhances the immunogenicity of a DNA vaccine encoding HLA-A*0201-restricted T-cell epitopes of Mycobacterium tuberculosis. Vaccine. 2004;22:1609\u20131615. doi: 10.1016/j.vaccine.2003.09.044.", "ArticleIdList": ["10.1016/j.vaccine.2003.09.044", "15068842"]}, {"Citation": "Glud S.Z., Bramsen J.B., Dagnaes-Hansen F., Wengel J., Howard K.A., Nyengaard J.R., Kjems J. Naked siLNA-mediated gene silencing of lung bronchoepithelium EGFP expression after intravenous administration. Oligonucleotides. 2009;19:163\u2013168. doi: 10.1089/oli.2008.0175.", "ArticleIdList": ["10.1089/oli.2008.0175", "19441893"]}, {"Citation": "Rolland A., Mumper R.J. 2001. Chitosan Related Compositions and Methods for Delivery of Nucleic Acids and Oligonucleotides into a Cell."}, {"Citation": "Iqbal M., Lin W., Jabbal-Gill I., Davis S.S., Steward M.W., Illum L. Nasal delivery of chitosan-DNA plasmid expressing epitopes of respiratory syncytial virus (RSV) induces protective CTL responses in BALB/c mice. Vaccine. 2003;21:1478\u20131485.", "ArticleIdList": ["12615444"]}, {"Citation": "Kumar M., Behera A.K., Matsuse H., Lockey R.F., Mohapatra S.S. Intranasal IFN-gamma gene transfer protects BALB/c mice against respiratory syncytial virus infection. Vaccine. 1999;18:558\u2013567.", "ArticleIdList": ["10519947"]}, {"Citation": "Mao H.Q., Roy K., Troung-Le V.L., Janes K.A., Lin K.Y., Wang Y., August J.T., Leong K.W. Chitosan-DNA nanoparticles as gene carriers: synthesis, characterization and transfection efficiency. J. Control. Release. 2001;70:399\u2013421.", "ArticleIdList": ["11182210"]}, {"Citation": "Raghuwanshi D., Mishra V., Das D., Kaur K., Suresh M.R. Dendritic cell targeted chitosan nanoparticles for nasal DNA immunization against SARS CoV nucleocapsid protein. Mol. Pharm. 2012;9:946\u2013956. doi: 10.1021/mp200553x.", "ArticleIdList": ["10.1021/mp200553x", "PMC3322645", "22356166"]}, {"Citation": "Rytting E., Nguyen J., Wang X., Kissel T. Biodegradable polymeric nanocarriers for pulmonary drug delivery. Expert Opin. Drug Deliv. 2008;5:629\u2013639. doi: 10.1517/17425247.5.6.629.", "ArticleIdList": ["10.1517/17425247.5.6.629", "18532919"]}, {"Citation": "Perez C., Sanchez A., Putnam D., Ting D., Langer R., Alonso M.J. Poly(lactic acid)-poly(ethylene glycol) nanoparticles as new carriers for the delivery of plasmid DNA. J. Control. Release. 2001;75:211\u2013224.", "ArticleIdList": ["11451511"]}, {"Citation": "Kircheis R., Wightman L., Wagner E. Design and gene delivery activity of modified polyethylenimines. Adv. Drug Deliv. Rev. 2001;53:341\u2013358.", "ArticleIdList": ["11744176"]}, {"Citation": "von Harpe A., Petersen H., Li Y., Kissel T. Characterization of commercially available and synthesized polyethylenimines for gene delivery. J. Control. Release. 2000;69:309\u2013322.", "ArticleIdList": ["11064137"]}, {"Citation": "Bivas-Benita M., Romeijn S., Junginger H.E., Borchard G. PLGA-PEI nanoparticles for gene delivery to pulmonary epithelium. Eur. J. Pharm. Biopharm. 2004;58:1\u20136. doi: 10.1016/j.ejpb.2004.03.008.", "ArticleIdList": ["10.1016/j.ejpb.2004.03.008", "PMC7127346", "15207531"]}, {"Citation": "Conti D.S., Brewer D., Grashik J., Avasarala S., da Rocha S.R.P. Poly(amidoamine) dendrimer nanocarriers and their aerosol formulations for siRNA delivery to the lung epithelium. Mol. Pharm. 2014;11:1808\u20131822. doi: 10.1021/mp4006358.", "ArticleIdList": ["10.1021/mp4006358", "PMC4051247", "24811243"]}, {"Citation": "Mhlwatika Z., Aderibigbe B.A. Application of dendrimers for the treatment of infectious diseases. Molecules. 2018;23 doi: 10.3390/molecules23092205.", "ArticleIdList": ["10.3390/molecules23092205", "PMC6225509", "30200314"]}, {"Citation": "Bharatwaj B., Mohammad A.K., Dimovski R., Cassio F.L., Bazito R.C., Conti D., Fu Q., Reineke J., da Rocha S.R.P. Dendrimer nanocarriers for transport modulation across models of the pulmonary epithelium. Mol. Pharm. 2015;12:826\u2013838. doi: 10.1021/mp500662z.", "ArticleIdList": ["10.1021/mp500662z", "PMC4350608", "25455560"]}, {"Citation": "Hatano K., Matsubara T., Muramatsu Y., Ezure M., Koyama T., Matsuoka K., Kuriyama R., Kori H., Sato T. Synthesis and influenza virus inhibitory activities of carbosilane dendrimers peripherally functionalized with hemagglutinin-binding Peptide. J. Med. Chem. 2014;57:8332\u20138339. doi: 10.1021/jm5007676.", "ArticleIdList": ["10.1021/jm5007676", "25249262"]}, {"Citation": "Khan O.F., Zaia E.W., Jhunjhunwala S., Xue W., Cai W., Yun D.S., Barnes C.M., Dahlman J.E., Dong Y., Pelet J.M., Webber M.J., Tsosie J.K., Jacks T.E., Langer R., Anderson D.G. Dendrimer-inspired nanomaterials for the in vivo delivery of siRNA to lung vasculature. Nano Lett. 2015;15:3008\u20133016. doi: 10.1021/nl5048972.", "ArticleIdList": ["10.1021/nl5048972", "PMC4825876", "25789998"]}, {"Citation": "Smola M., Vandamme T., Sokolowski A. Nanocarriers as pulmonary drug delivery systems to treat and to diagnose respiratory and non respiratory diseases. Int. J. Nanomed. 2008;3:1\u201319.", "ArticleIdList": ["PMC2526354", "18488412"]}, {"Citation": "Pellosi D.S., d'Angelo I., Maiolino S., Mitidieri E., d'Emmanuele di Villa Bianca R., Sorrentino R., Quaglia F., Ungaro F. In vitro/in vivo investigation on the potential of Pluronic(R) mixed micelles for pulmonary drug delivery. Eur. J. Pharm. Biopharm. 2018;130:30\u201338. doi: 10.1016/j.ejpb.2018.06.006.", "ArticleIdList": ["10.1016/j.ejpb.2018.06.006", "29890256"]}, {"Citation": "Grenha A., Seijo B., Remunan-Lopez C. Microencapsulated chitosan nanoparticles for lung protein delivery. Eur. J. Pharm. Sci. 2005;25:427\u2013437. doi: 10.1016/j.ejps.2005.04.009.", "ArticleIdList": ["10.1016/j.ejps.2005.04.009", "15893461"]}, {"Citation": "Learoyd T.P., Burrows J.L., French E., Seville P.C. Sustained delivery by leucine-modified chitosan spray-dried respirable powders. Int. J. Pharm. 2009;372:97\u2013104. doi: 10.1016/j.ijpharm.2009.01.017.", "ArticleIdList": ["10.1016/j.ijpharm.2009.01.017", "19429272"]}, {"Citation": "Wang J.-C., Lai S., Guo X., Zhang X., de Crombrugghe B., Sonnylal S., Arnett F.C., Zhou X. Attenuation of fibrosis in vitro and in vivo with SPARC siRNA. Arthritis Res. Ther. 2010;12 doi: 10.1186/ar2973. R60.", "ArticleIdList": ["10.1186/ar2973", "PMC2888211", "20359365"]}, {"Citation": "Yoon P.O., Park J.W., Lee C.-M., Kim S.H., Kim H.-N., Ko Y., Bae S.J., Yun S., Park J.H., Kwon T., Kim W.S., Lee J., Lu Q., Kang H.-R., Cho W.-K., Elias J.A., Yang J.-S., Park H.-O., Lee K., Lee C.G. Self-assembled micelle interfering RNA for effective and safe targeting of dysregulated genes in pulmonary fibrosis. J. Biol. Chem. 2016;291:6433\u20136446. doi: 10.1074/jbc.M115.693671.", "ArticleIdList": ["10.1074/jbc.M115.693671", "PMC4813554", "26817844"]}, {"Citation": "Gaber N.N., Darwis Y., Peh K.-K., Tan Y.T.-F. Characterization of polymeric micelles for pulmonary delivery of beclomethasone dipropionate. J. Nanosci. Nanotechnol. 2006;6:3095\u20133101.", "ArticleIdList": ["17048523"]}, {"Citation": "Lin B., Vora G.J., Thach D., Walter E., Metzgar D., Tibbetts C., Stenger D.A. Use of oligonucleotide microarrays for rapid detection and serotyping of acute respiratory disease-associated adenoviruses. J. Clin. Microbiol. 2004;42:3232\u20133239.", "ArticleIdList": ["PMC446281", "15243087"]}, {"Citation": "Roth S.B., Jalava J., Ruuskanen O., Ruohola A., Nikkari S. Use of an oligonucleotide array for laboratory diagnosis of bacteria responsible for acute upper respiratory infections. J. Clin. Microbiol. 2004;42:4268\u20134274.", "ArticleIdList": ["PMC516371", "15365022"]}, {"Citation": "Popescu F.-D., Popescu F. A review of antisense therapeutic interventions for molecular biological targets in asthma. Biologics. 2007;1:271\u2013283.", "ArticleIdList": ["PMC2721314", "19707336"]}, {"Citation": "Krutzfeldt J., Rajewsky N., Braich R., Rajeev K.G., Tuschl T., Manoharan M., Stoffel M. Silencing of microRNAs in vivo with \u201cantagomirs\u201d. Nature. 2005;438:685\u2013689. doi: 10.1038/nature04303.", "ArticleIdList": ["10.1038/nature04303", "16258535"]}, {"Citation": "Juliano R.L., Carver K. Cellular uptake and intracellular trafficking of oligonucleotides. Adv. Drug Deliv. Rev. 2015;87:35\u201345. doi: 10.1016/j.addr.2015.04.005.", "ArticleIdList": ["10.1016/j.addr.2015.04.005", "PMC4504789", "25881722"]}, {"Citation": "Pavord I.D., Korn S., Howarth P., Bleecker E.R., Buhl R., Keene O.N., Ortega H., Chanez P. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet (London, England) 2012;380:651\u2013659. doi: 10.1016/S0140-6736(12)60988-X.", "ArticleIdList": ["10.1016/S0140-6736(12)60988-X", "22901886"]}, {"Citation": "Kang S.P., Saif M.W. Infusion-related and hypersensitivity reactions of monoclonal antibodies used to treat colorectal cancer--identification, prevention, and management. J. Support. Oncol. 2007;5:451\u2013457.", "ArticleIdList": ["18019853"]}, {"Citation": "Trainer P.J., Newell-Price J.D.C., Ayuk J., Aylwin S.J.B., Rees A., Drake W., Chanson P., Brue T., Webb S.M., Fajardo C., Aller J., McCormack A.I., Torpy D.J., Tachas G., Atley L., Ryder D., Bidlingmaier M. A randomised, open-label, parallel group phase 2 study of antisense oligonucleotide therapy in acromegaly. Eur. J. Endocrinol. 2018;179:97\u2013108. doi: 10.1530/EJE-18-0138.", "ArticleIdList": ["10.1530/EJE-18-0138", "PMC6063983", "29789410"]}, {"Citation": "McClorey G., Wood M.J. An overview of the clinical application of antisense oligonucleotides for RNA-targeting therapies. Curr. Opin. Pharmacol. 2015;24:52\u201358. doi: 10.1016/j.coph.2015.07.005.", "ArticleIdList": ["10.1016/j.coph.2015.07.005", "26277332"]}, {"Citation": "Stein C.A., Castanotto D. FDA-approved oligonucleotide therapies in 2017. Mol. Ther. 2017;25:1069\u20131075. doi: 10.1016/j.ymthe.2017.03.023.", "ArticleIdList": ["10.1016/j.ymthe.2017.03.023", "PMC5417833", "28366767"]}, {"Citation": "Kurreck J. Antisense technologies. Improvement through novel chemical modifications. Eur. J. Biochem. 2003;270:1628\u20131644.", "ArticleIdList": ["12694176"]}, {"Citation": "Allakhverdi Z., Allam M., Guimond A., Ferrari N., Zemzoumi K., Seguin R., Paquet L., Renzi P.M. Multitargeted approach using antisense oligonucleotides for the treatment of asthma. Ann. N. Y. Acad. Sci. 2006;1082:62\u201373. doi: 10.1196/annals.1348.047.", "ArticleIdList": ["10.1196/annals.1348.047", "17145927"]}, {"Citation": "Juliano R.L. The delivery of therapeutic oligonucleotides. Nucleic Acids Res. 2016;44:6518\u20136548. doi: 10.1093/nar/gkw236.", "ArticleIdList": ["10.1093/nar/gkw236", "PMC5001581", "27084936"]}]}], "History": [{"Year": "2019", "Month": "4", "Day": "5"}, {"Year": "2019", "Month": "4", "Day": "30"}, {"Year": "2019", "Month": "5", "Day": "15"}, {"Year": "2019", "Month": "5", "Day": "29", "Hour": "6", "Minute": "0"}, {"Year": "2019", "Month": "7", "Day": "23", "Hour": "6", "Minute": "0"}, {"Year": "2019", "Month": "5", "Day": "29", "Hour": "6", "Minute": "0"}, {"Year": "2019", "Month": "5", "Day": "25"}], "PublicationStatus": "ppublish", "ArticleIdList": ["31136735", "PMC7094617", "10.1016/j.cbi.2019.05.028", "S0009-2797(19)30575-7"]}}]}